Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
-
* Corresponding author: Jan O Friedrich j.friedrich@utoronto.ca
Critical Care 2006, 10:145 doi:10.1186/cc4947
Accesses
- Last 30 days: 33 accesses
- Last year: 473 accesses
- All time: 5812 accesses
Cited by
BioMed Central: 7 citations
|
Commentary
Effect of sepsis therapies on health-related quality of life Sara E Erickson, Greg S Martin Critical Care 2008, 12:109 (22 January 2008) |
|
Research article
Vania Costa, James M Brophy BMC Anesthesiology 2007, 7:5 (25 June 2007) A systematic review and economic analysis of the use of drotecogin alpha questions its clinical efficacy and cost effectiveness in the treatment of adults with sepsis, including those with higher disease severity.
|
|
Letter
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death Jan O Friedrich, Neill KJ Adhikari, Maureen O Meade Critical Care 2006, 10:427 (20 December 2006) |
|
Letter
Mark D Williams, Jonathan M Janes, David R Nelson Critical Care 2006, 10:424 (30 October 2006) |
|
Letter
Drotrecogin alfa (activated): down and not out, but not really in either Jan O Friedrich, Neill KJ Adhikari, Maureen O Meade Critical Care 2006, 10:420 (22 September 2006) |
|
Letter
Patience and change: a conflict of interests? Manoj K Saxena, Peter JD Andrews Critical Care 2006, 10:422 (19 September 2006) |
|
Letter
Activated protein C in sepsis: down but not out, yet Ritesh Agarwal, Alok Nath Critical Care 2006, 10:416 (26 July 2006) |